IASLC issues statement paper on liquid biopsy for lung cancer
Share

DENVER – The lungs can be a difficult organ to biopsy with a needle, so the promise of identifying lung cancer through a blood-based biopsy has lung cancer experts and patients optimistic. Knowing how and when to use a liquid biopsy is critically important and led global experts at the International Association for the Study of Lung Cancer (IASLC) to issue “The IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC),” now available online in the Journal of Thoracic Oncology.

“Liquid biopsy and its subsequent molecular analysis is a powerful tool that can determine the patient’s molecular tumor profile in order to determine the best therapeutic option and can be applied as an alternative to tissue testing in cases where tumor testing is not possible or tissue is not adequate,” said Fred R. Hirsch, MD, PhD, and CEO of the IASLC. “Gathering experts to collect and interpret a vast amount of information and to distribute best practices ensures that general oncologists and clinicians have access to the latest and best information in the emerging field of liquid biopsies.”

Historically, tissue biopsy specimens have been the sole source of tumor molecular information, but unfortunately, adequate tissue is

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD